State Street
DYN icon

State Street’s Dyne Therapeutics DYN Stock Holding History

State Street’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121M Sell
6,653,746
-38,999
-0.6% -$672K ﹤0.01% 1274
2025
Q4 		$131M Buy
6,692,745
+1,423,828
+27% +$27M ﹤0.01% 1200
2025
Q3 		$66.7M Buy
5,268,917
+1,913,239
+57% +$21.8M ﹤0.01% 1585
2025
Q2 		$31.9M Sell
3,355,678
-253,973
-7% -$2.8M ﹤0.01% 1929
2025
Q1 		$37.8M Sell
3,609,651
-107,732
-3% -$1.54M ﹤0.01% 1793
2024
Q4 		$87.6M Buy
3,717,383
+75,524
+2% +$2.23M ﹤0.01% 1418
2024
Q3 		$131M Buy
3,641,859
+440,890
+14% +$17.5M 0.01% 1171
2024
Q2 		$113M Sell
3,200,969
-992,584
-24% -$28.8M ﹤0.01% 1183
2024
Q1 		$119M Buy
4,193,553
+1,856,412
+79% +$42M 0.01% 1197
2023
Q4 		$31.1M Buy
2,337,141
+398,499
+21% +$3.89M ﹤0.01% 1959
2023
Q3 		$17.4M Buy
1,938,642
+158,902
+9% +$1.71M ﹤0.01% 2244
2023
Q2 		$20M Buy
1,779,740
+1,178,928
+196% +$13.9M ﹤0.01% 2247
2023
Q1 		$6.92M Buy
600,812
+24,669
+4% +$320K ﹤0.01% 2861
2022
Q4 		$6.68M Sell
576,143
-2,737
-0.5% -$31.7K ﹤0.01% 2906
2022
Q3 		$7.35M Buy
578,880
+19,192
+3% +$220K ﹤0.01% 2870
2022
Q2 		$3.85M Buy
559,688
+58,717
+12% +$405K ﹤0.01% 3223
2022
Q1 		$4.83M Buy
500,971
+8,618
+2% +$73.4K ﹤0.01% 3198
2021
Q4 		$5.85M Buy
492,353
+7,593
+2% +$107K ﹤0.01% 3164
2021
Q3 		$7.87M Buy
484,760
+25,864
+6% +$459K ﹤0.01% 3009
2021
Q2 		$9.65M Buy
458,896
+231,492
+102% +$4.35M ﹤0.01% 2937
2021
Q1 		$3.53M Buy
227,404
+5,400
+2% +$105K ﹤0.01% 3197
2020
Q4 		$4.66M Buy
+222,004
New +$4.39M ﹤0.01% 3000

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street's DYN Position: Q1 2026 in Review

State Street reduced its Dyne Therapeutics (DYN) stake by 0.58% in Q1 2026, selling an estimated $672K and leaving 6,653,746 shares worth $121M. The position accounts for ﹤0.01% of the portfolio, ranked #1274.

State Street first reported a position in DYN in Q4 2020 and has held it in 22 quarters since. The position peaked at $131M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • State Street held 6,653,746 shares of Dyne Therapeutics worth $121M as of Q1 2026.
  • State Street sold 38,999 Dyne Therapeutics shares in Q1 2026, an estimated $672K.
  • Dyne Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1274 holding.
  • State Street first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • State Street's Dyne Therapeutics position peaked at $131M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.